Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#1 / 116 Total
ELAB - Elevai Labs Inc. - Stock Price Chart
TickerELAB [NASD]
CompanyElevai Labs Inc.
CountryUSA
IndustryBiotechnology
Market Cap2.77MEPS (ttm)-0.30
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S1.12EPS next 5Y-
P/B0.95EPS Q/Q-13.20%
Dividend-Sales Q/Q335.95%
Insider Own59.30%Inst Own6.77%
Insider Trans0.00%Inst Trans-
Short Float7.78%EarningsAug 14/b
Analyst Recom-Target Price-
Avg Volume4.84M52W Range0.08 - 4.24
Today 07:30AM Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations (GlobeNewswire) +56.10%
Oct-02-24 08:30AM Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Launch of Clinical Study Combining Its Flagship Topical Exosome Skincare Products with a Medical Aesthetic Energy Device (GlobeNewswire)
Sep-26-24 09:42PM Altium Capital Management LP Acquires New Stake in Elevai Labs Inc (GuruFocus.com) -15.24%
Sep-24-24 05:00PM Univest Securities, LLC Announces Closing of $8.0 Million Registered Follow-on Offering for its Client Elevai Labs Inc. (NASDAQ: ELAB) (GlobeNewswire)
Sep-23-24 08:45AM Elevai Labs Inc. Announces Pricing of $8.0 Million Public Offering (GlobeNewswire) -62.00%
Sep-10-24 07:30AM Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Results for E-Series Exosome Technology in Potential Melasma Applications (GlobeNewswire)
Sep-03-24 07:30AM Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Encouraging Data Results Indicating Potential for Hair Restoration Using Proprietary Exosome Technology (GlobeNewswire) +20.12%
Aug-28-24 07:30AM Elevai Labs Inc. Files Combination Patents with Yuva Biosciences for Breakthrough Hair and Scalp Care Technology Utilizing YuvaBio? Y100 Mitochondrial Innovation and Elevai Exosomes (GlobeNewswire) -12.28%
Aug-26-24 07:30AM Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Data Results with Completion of Clinical Study of Elevai Enfinity Topical Exosome Serum (GlobeNewswire)
Aug-19-24 09:00AM Elevai Labs Inc. Subsidiary, Elevai Research Inc., Announces Preliminary Positive Research Data Highlighting the Potential of Proprietary Exosome Technology for Skin Health Applications (GlobeNewswire)
Elevai Labs, Inc. is a physician-dispensed skincare company, which engages in the research and development of skincare formulations. It is involved in the production and commercialization of topical skincare products that contain its proprietary stem cell-derived Elevai Exosomes. The company was founded by Hatem Abou-Sayed and Jordan R. Plews in 2020 and is headquartered in Newport Beach, CA.
EVGO - EVgo Inc - Stock Price Chart
TickerEVGO [NASD, RUT]
CompanyEVgo Inc
CountryUSA
IndustrySpecialty Retail
Market Cap654.89MEPS (ttm)-0.41
P/E-EPS this Y6.41%
Forward P/E-EPS next Y27.39%
PEG-EPS past 5Y-
P/S3.17EPS next 5Y-
P/B47.68EPS Q/Q-19.46%
Dividend-Sales Q/Q31.78%
Insider Own6.41%Inst Own45.01%
Insider Trans1.21%Inst Trans-1.04%
Short Float25.94%EarningsAug 01/b
Analyst Recom1.83Target Price5.55
Avg Volume3.38M52W Range1.65 - 4.80
TodayUpgrade JP Morgan Neutral → Overweight $7
TodayUpgrade TD Cowen Hold → Buy $5 → $7
EVgo, Inc. engages in the provision of electric vehicle charging station services. It offers the EVgo network, home charging solutions, work charging solutions, and freedom station plans to electric car owners. The company was founded in October 2010 and is headquartered in Los Angeles, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sullivan FrancineChief Legal OfficerAug 12 '24Sale3.6012,58445,277117,327Aug 13 07:27 PM
KISH DENNIS GPresidentAug 12 '24Sale3.6016,41459,10247,614Aug 13 07:25 PM
KISH DENNIS GOfficerAug 12 '24Proposed Sale3.6616,41460,075Aug 12 04:04 PM
Sullivan FrancineOfficerAug 12 '24Proposed Sale3.6612,58446,057Aug 12 04:03 PM
Lee StephanieInterim CFOJul 02 '24Sale2.342,4775,79628,753Jul 03 06:54 PM
HKD - AMTD Digital Inc ADR - Stock Price Chart
TickerHKD [NYSE]
CompanyAMTD Digital Inc ADR
CountryFrance
IndustrySoftware - Application
Market Cap139.61MEPS (ttm)-
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y107.64%
P/S-EPS next 5Y-
P/B-EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own-Inst Own0.51%
Insider Trans-Inst Trans-87.16%
Short Float2.18%Earnings-
Analyst Recom-Target Price-
Avg Volume324.47K52W Range2.61 - 6.18
AMTD Digital, Inc. is a holding company, which engages in the development of digital solutions applications under AMTD SpiderNet platform. It operates through the following segments: Digital Solutions Services-Non Financial Services; Digital Solutions Services-Financial Services; Hotel Operations, Hospitality, and VIP Services; and Digital Media, Content, and Marketing Services, and Others. The Digital Solutions Services-Non Financial Services segment offers paid access to the AMTD SpiderNet ecosystem for investor communications, investor relations, and corporate communications. The Digital Solutions Services-Financial Services segment provides insurance brokerage services. The Hotel Operations, Hospitality, and VIP Services segment is associated with hotel investments and related services. The Digital Media, Content, and Marketing Services, and Others segment promotes digital solutions and digital medium through a library of digital videos and online media platforms. The company was founded on September 12, 2019 and is headquartered in Paris, France.
TOVX - Theriva Biologics Inc - Stock Price Chart
TickerTOVX [AMEX]
CompanyTheriva Biologics Inc
CountryUSA
IndustryBiotechnology
Market Cap2.15MEPS (ttm)-31.09
P/E-EPS this Y7.02%
Forward P/E-EPS next Y30.19%
PEG-EPS past 5Y51.06%
P/S-EPS next 5Y-
P/B0.05EPS Q/Q-27.92%
Dividend-Sales Q/Q-
Insider Own1.46%Inst Own4.10%
Insider Trans0.00%Inst Trans-14.25%
Short Float6.84%EarningsAug 13/b
Analyst Recom1.00Target Price100.00
Avg Volume681.79K52W Range1.24 - 17.11
Theriva Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-020 and SYN-004. SYN-020 is intended to prevent the antibiotic-mediated microbiome damage, C. difficile infections (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host disease (aGVHD) in allogeneic HCT recipients. SYN-004 is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.
INV - Learn CW Investment Corp - Stock Price Chart
TickerINV [NASD]
CompanyLearn CW Investment Corp
CountryUSA
IndustryShell Companies
Market Cap209.60MEPS (ttm)-0.35
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B2.41EPS Q/Q-329.01%
Dividend-Sales Q/Q-
Insider Own43.21%Inst Own55.19%
Insider Trans0.00%Inst Trans2.27%
Short Float0.07%Earnings-
Analyst Recom-Target Price-
Avg Volume62.89K52W Range8.70 - 12.91
Learn CW Investment Corp. is a blank check company, which engages in effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business combination with one or more businesses. The company was founded by Robert Joseph Hutter in 2008 and is headquartered in Los Angeles, CA.
BBLG - Bone Biologics Corp - Stock Price Chart
TickerBBLG [NASD]
CompanyBone Biologics Corp
CountryUSA
IndustryMedical Devices
Market Cap1.00MEPS (ttm)-9.78
P/E-EPS this Y90.68%
Forward P/E-EPS next Y30.91%
PEG-EPS past 5Y42.24%
P/S-EPS next 5Y-
P/B0.85EPS Q/Q95.04%
Dividend-Sales Q/Q-
Insider Own2.33%Inst Own10.75%
Insider Trans0.00%Inst Trans-52.61%
Short Float5.51%EarningsAug 28
Analyst Recom1.00Target Price16.75
Avg Volume4.94M52W Range0.80 - 10.56
Bone Biologics Corp. operates as a medical device company. engages in the research and development of bone regeneration in spinal fusion. Its product is Nell-1, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. Its platform technology has application in delivering improved outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. The company was founded by Eric Kang Ting, Chia Soo and Benjamin Wu in 2004 and is headquartered in Burlington, MA.
VRCA - Verrica Pharmaceuticals Inc - Stock Price Chart
TickerVRCA [NASD, RUT]
CompanyVerrica Pharmaceuticals Inc
CountryUSA
IndustryBiotechnology
Market Cap57.63MEPS (ttm)-1.88
P/E-EPS this Y0.91%
Forward P/E-EPS next Y45.60%
PEG-EPS past 5Y-0.97%
P/S4.14EPS next 5Y-
P/B-EPS Q/Q-54.39%
Dividend-Sales Q/Q2744.51%
Insider Own38.89%Inst Own43.78%
Insider Trans-1.46%Inst Trans-9.30%
Short Float12.48%EarningsAug 14/b
Analyst Recom1.40Target Price14.50
Avg Volume730.31K52W Range1.04 - 11.41
Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its products include Pipeline VP-102, Pipeline VP-103, and Pipeline VP-315. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hayes Christopher G.CHIEF LEGAL OFFICERAug 26 '24Sale2.6626,18369,647115,303Aug 28 04:15 PM
Hayes Christopher G.CHIEF LEGAL OFFICERAug 27 '24Sale2.469,53023,444105,773Aug 28 04:15 PM
Goldenberg GaryChief Medical OfficerAug 26 '24Sale2.669,88826,30297,862Aug 28 04:15 PM
Goldenberg GaryChief Medical OfficerAug 27 '24Sale2.463,6018,85894,261Aug 28 04:15 PM
Bonaccorso JoeCHIEF COMMERCIAL OFFICERAug 26 '24Sale2.6624,70965,72682,107Aug 28 04:15 PM
WHLR - Wheeler Real Estate Investment Trust Inc - Stock Price Chart
TickerWHLR [NASD]
CompanyWheeler Real Estate Investment Trust Inc
CountryUSA
IndustryREIT - Retail
Market Cap9.96MEPS (ttm)-11112.28
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y32.52%
P/S0.10EPS next 5Y-
P/B-EPS Q/Q98.20%
Dividend-Sales Q/Q5.23%
Insider Own0.38%Inst Own19.62%
Insider Trans-97.07%Inst Trans-
Short Float25.41%Earnings-
Analyst Recom3.00Target Price5.00
Avg Volume1.74M52W Range2.90 - 1126.80
Wheeler Real Estate Investment Trust, Inc. engages in the acquisition, finance, development, lease, ownership, and management of retail properties. Its property portfolio includes income producing, strip centers, neighborhood, grocery-anchored, community, and free-standing retail properties. The company was founded on June 23, 2011 and is headquartered in Virginia Beach, VA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MAGNOLIA CAPITAL FUND, LP10% OwnerSep 18 '24Sale20.4011,700238,680249,626Sep 19 06:03 PM
MAGNOLIA CAPITAL FUND, LP10% OwnerSep 17 '24Sale20.489,380192,102261,326Sep 19 06:03 PM
MAGNOLIA CAPITAL FUND, LP10% OwnerSep 11 '24Sale20.304,55092,365270,706Sep 13 05:20 PM
MAGNOLIA CAPITAL FUND, LP10% OwnerSep 05 '24Sale19.1713,500258,795280,289Sep 09 05:25 PM
MAGNOLIA CAPITAL FUND, LP10% OwnerSep 09 '24Sale20.155,033101,415275,256Sep 09 05:25 PM
INDO - Indonesia Energy Corp Ltd - Stock Price Chart
TickerINDO [AMEX]
CompanyIndonesia Energy Corp Ltd
CountryIndonesia
IndustryOil & Gas E&P
Market Cap43.30MEPS (ttm)-0.26
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S12.27EPS next 5Y-
P/B2.93EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own53.26%Inst Own0.70%
Insider Trans0.00%Inst Trans-62.92%
Short Float5.27%Earnings-
Analyst Recom1.00Target Price10.00
Avg Volume4.74M52W Range2.03 - 6.65
Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.
SGMT - Sagimet Biosciences Inc - Stock Price Chart
TickerSGMT [NASD]
CompanySagimet Biosciences Inc
CountryUSA
IndustryBiotechnology
Market Cap129.12MEPS (ttm)-1.14
P/E-EPS this Y43.11%
Forward P/E-EPS next Y-134.80%
PEG-EPS past 5Y-16.23%
P/S64.56EPS next 5Y-
P/B0.70EPS Q/Q19.85%
Dividend-Sales Q/Q-
Insider Own34.36%Inst Own53.34%
Insider Trans-0.51%Inst Trans-
Short Float9.77%EarningsAug 14/b
Analyst Recom1.33Target Price32.60
Avg Volume1.08M52W Range2.13 - 20.71
Oct-01-24 07:00AM Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH (GlobeNewswire) +12.64%
12:05AM Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-12-24 07:30AM Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit (GlobeNewswire) -9.57%
Sep-04-24 08:00AM Sagimet Biosciences to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-14-24 08:00AM Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire) -7.14%
Aug-01-24 08:00AM Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors (GlobeNewswire)
Jun-10-24 08:00AM Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat (GlobeNewswire)
Jun-06-24 05:00AM Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024 (GlobeNewswire)
May-16-24 08:00AM Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024 (GlobeNewswire)
May-15-24 12:53PM SGMT Stock Earnings: Sagimet Biosciences Beats EPS for Q1 2024 (InvestorPlace) +5.48%
Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kemble GeorgeExecutive ChairmanJul 23 '24Sale3.1723,62574,830118,693Jul 25 04:05 PM
Martins Eduardo BrunoChief Medical OfficerJul 19 '24Sale3.108,35725,91081,213Jul 23 04:06 PM
Rozek ElizabethGeneral Counsel and CCOJul 19 '24Sale3.1010,91433,830160,506Jul 23 04:05 PM
Kemble GeorgeExecutive ChairmanJul 19 '24Sale3.1014,06243,605142,318Jul 23 04:05 PM
Happel DavidPresident & CEOMar 26 '24Buy5.2712,10063,731639,200Mar 28 04:08 PM
1234561012